Xbiotech INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
XBIT
Xbiotech INCXBiotech Inc. has filed an amendment to its 2025 Form 10-K, primarily to include previously omitted Part III information regarding directors, executive officers, and corporate governance.
NASDAQ
XBIT
Xbiotech INCXBiotech Inc. reported a net loss of $45.5 million for fiscal year 2025, driven by increased R&D expenses and executive severance, while highlighting positive oncology clinical trial results and ongoing regulatory discussions for Natrunix.
NASDAQ
XBIT
Xbiotech INCXBiotech Inc. amends its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
XBIT
Xbiotech INC10-K: XBiotech Inc. Reports FY 2024 Results, Pauses Infrastructure Expansion Amidst Regulatory Uncertainty
XBiotech Inc. reports a net loss for FY 2024, pauses construction of new facilities, and awaits FDA clarification on regulatory paths for its cancer and arthritis programs.
NASDAQ
XBIT
Xbiotech INCXBiotech Inc. has filed an amendment to its annual report to correct certain information regarding its directors.
NASDAQ
XBIT
Xbiotech INC10-K/A: XBiotech Amends Annual Report to Include Omitted Information on Directors and Executive Compensation
XBiotech Inc. filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
NASDAQ
XBIT
Xbiotech INCXBiotech Inc. reports a net loss for 2023 while progressing its pipeline of True Human antibody therapeutics, including two anti-IL-1a product candidates.